GLP1R and type 2 diabetes mellitus: IVW analysis showed that genetically predicted GLP‐1R agonist exposure was associated with a reduction in BMI (β = −0.063, 95% confidence interval [CI]: −0.10 to −0.03, p = 8.43 × 10−4) and a decreased risk of T2DM (odds ratio [OR] = 0.80, 95% CI: 0.65 to 0.98, p = 0.032), supporting the validity of the genetic instruments.